Liquidia Corp (LQDA) · Aug 12, 2026 · Earnings

Profitability surged—but the YUTREPIA ramp still came in just shy

Miss — Revenue $171.7M vs ~$171.9M consensus; diluted EPS $0.74 vs ~$0.75

YUTREPIA generated $170.4M in sales and $74.7M in profit, yet revenue and diluted EPS landed slightly below expectations.

The quarter was essentially in line, but not a beat. Liquidia reported $171.7 million of revenue and $0.74 diluted EPS, versus published expectations of approximately $171.9 million and $0.75, respectively—small misses on both headline measures.

MetricQ2 2026Q2 2025Expectation
Product sales, net$170.4M (Product sales, net)$6.5M (Product sales, net)—
Total revenue$171.7M (Income Statement)$8.8M (Income Statement)~$171.9M
Net income$74.7M (Income Statement)$(41.6)M (Income Statement)—
Diluted EPS$0.74 (Income Statement)$(0.49) (Income Statement)~$0.75
Adjusted EBITDA$96.3M (Reconciliation of Non-GAAP Financial Information)——
Cash and equivalents$284.2M (Balance Sheet)$190.7M at December 31, 2025 (Balance Sheet)—

YUTREPIA has become a real commercial engine, but the growth was already the central expectation. Product sales reached $170.4 million, up from $6.5 million a year earlier, and the company posted its fourth consecutive profitable quarter. That confirms the commercial launch is scaling, but the result does not show a meaningful upside surprise against the roughly $172 million revenue bar.

Profitability improved dramatically despite heavier investment. Net income reached $74.7 million and adjusted EBITDA $96.3 million, while research and development rose 185% to $17.2 million and selling, general and administrative expense increased 48% to $57.4 million. The key takeaway is operating leverage: YUTREPIA's sales growth more than absorbed the higher commercial and L606 spending. (Income Statement)

The balance sheet provides more room to fund the next phase. Cash and equivalents rose to $284.2 million from $190.7 million at December 31, 2025, while stockholders' equity increased to $195.1 million from $44.7 million. That supports continued L606 development and commercialization without an immediate financing signal in this filing. (Balance Sheet)

The net read is a narrow miss, not a thesis break. The filing confirms strong YUTREPIA adoption, rising profitability, and progress toward Re-Spire enrollment, but it does not raise an outlook or deliver financial upside beyond what the market was already expecting. The remaining strategic uncertainty is whether L606 can broaden the growth story and how ongoing litigation could affect YUTREPIA's ability to remain on the market. (Corporate update; Risk factors)

What to watch next

Re-Spire enrollment and upcoming Q3 results

Original filing on SEC EDGAR

More Liquidia Corp news

Profitability surged—but the YUTREPIA ramp still came in just shy | LQDA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.